Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101576 | 0.85 | LMNA (0.39) | ALDH1A1ALOX15 | |
| SCHEMBL22101613 | 0.85 | ESR1 (0.33) | ALDH1A1TP53CYP3A4ALOX15HIF1A | |
| SCHEMBL22101610 | 0.85 | ALDH1A1 (0.34) | HDAC1ALDH1A1HPGD | |
| SCHEMBL22101951 | 0.85 | — | — | |
| SCHEMBL22101652 | 0.84 | KMT2A (0.39) | HPGD | |
| SCHEMBL22101642 | 0.84 | TSHR (0.41) | ADRA2AADRA2BADRA2CALDH1A1HPGD | |
| SCHEMBL22101658 | 0.84 | KMT2A (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL22101983 | 0.84 | CYP19A1 (0.35) | — | |
| SCHEMBL22101627 | 0.84 | TPMT (0.33) | — | |
| SCHEMBL22101956 | 0.83 | GAA (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172977-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | ADRA2A 3985/4885ADRA2B 4761/4885ADRA2C 4432/4885 |
| US-20200188430-A1 | THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAME | TUFM, SMN1; SMN2, MCU | ADRA2A 3985/4885ADRA2B 4761/4885ADRA2C 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.